2,6-dimethyl-carbazole | 78787-80-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 2,6-dimethyl-carbazole
• 英文别名: 2,6-Dimethyl-carbazol；2,6-Dimethyl-9H-carbazole
• CAS: 78787-80-1
• 化学式: C₁₄H₁₃N
• 分子量: 195.264
• InChiKey: JEQGMFVANDIHGJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  15
• 可旋转键数：
  0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  15.8
• 氢给体数：
  1
• 氢受体数：
  0

反应信息

• 作为反应物：
  描述：

  2,6-dimethyl-carbazole 在 溶剂黄146 、 sodium nitrite 作用下， 生成 2,6-dimethyl-9-nitroso-carbazole
  参考文献：
  名称：

  CXCI.—重氮氨基对甲苯的热解

  摘要：

  DOI：

  10.1039/jr9300001502
• 作为产物：
  描述：

  1,3-di(p-tolyl)triaz-1-ene 在 calcium oxide 作用下， 生成 2,6-dimethyl-carbazole
  参考文献：
  名称：

  CXCI.—重氮氨基对甲苯的热解

  摘要：

  DOI：

  10.1039/jr9300001502

文献信息

• A Tandem Reduction-Oxidation Protocol for the Conversion of 1-Keto-1,2,3,4-tetrahydrocarbazoles to Carbazoles via Tosylhydrazones through Microwave Assistance: Efficient Synthesis of Glycozoline, Clausenalene, Glycozolicine, and Deoxycarbazomycin B and th
  作者：Suchandra Chakraborty、Gautam Chattopadhyay、Chandan Saha

  DOI：10.1002/jhet.999

  日期：2013.1

  methodology for the synthesis of carbazoles from 1‐keto‐1,2,3,4‐tetrahydrocarbazoles via the corresponding tosylsulfonhydrazones by a one‐pot tandem reduction–oxidation protocol using a combination of NaBH4 and Pd–C on MgSO4·7H2O, a solid support, under microwave is developed. The reaction is successfully extended toward the synthesis of several naturally occurring carbazole alkaloids, namely 3‐methylcarbazole

  一种新颖高效的方法，通过NaBH 4和Pd-C的组合，通过一锅串联还原-氧化方案，通过相应的甲苯磺酰基hydr肼，通过相应的甲苯磺酰基hydr，由1-酮，1,2,3,4-四氢咔唑合成咔唑在微波作用下形成了4 ·7H 2 O（一种固体支持物）。该反应已成功地扩展到几种天然存在的咔唑生物碱的合成，即3-甲基咔唑，糖唑啉，黄嘌呤，糖唑啉，墨瑞福林A和脱氧咔唑霉素B（一种已知具有良好抗菌活性的咔唑衍生物）。
• HEPATITIS C VIRUS INHIBITORS
  申请人：Qiu Yao-Ling

  公开号：US20120039848A1

  公开（公告）日：2012-02-16

  The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

  本发明揭示了公式（I）的化合物或其药学上可接受的盐、酯或前药，它们能够抑制RNA含量病毒，特别是丙型肝炎病毒（HCV）。因此，本发明的化合物干扰了丙型肝炎病毒的生命周期，并且也可用作抗病毒剂。本发明还涉及包含上述化合物的制药组合物，用于治疗患有HCV感染的受试者。本发明还涉及通过给受试者投予包含本发明化合物的制药组合物来治疗HCV感染的方法。
• HIGH PENETRATION COMPOSITIONS AND USES THEREOF
  申请人：Yu Chongxi

  公开号：US20090238763A1

  公开（公告）日：2009-09-24

  The present invention relates to compositions and uses of novel high penetration compositions or high penetration prodrugs (HPP), in particular HPPs for non-steroidal anti-inflammatory agents (NSAIAs), which are capable of crossing biological barriers with high penetration efficiency. The HPPs herein are capable of being converted to parent active drugs or drug metabolites after crossing the biological barrier and thus can render treatments for the conditions that the parent drugs or metabolites can. Additionally, due to the ability of penetrating biological barriers, the HPPs herein are capable of reaching areas that parent drugs may not be able to access or to render a sufficient concentration at the target areas and therefore render novel treatments. The HPPs herein can be administered to a subject through various administration routes. For example, the HPPs can be locally delivered to an action site of a condition with a high concentration due to their ability of penetrating biological barriers and thus obviate the need for a systematic administration. For another example, the HPPs herein can be systematically administer to a biological subject and enter the general circulation with a faster rate.

  本发明涉及新型高渗透性组合物或高渗透性前药（HPP）的组成和用途，特别是用于非甾体抗炎药（NSAIAs）的HPP，其能够高效地穿过生物屏障。这里的HPP能够在穿过生物屏障后转化为父活性药物或药物代谢物，从而可以治疗与父药物或代谢物相关的疾病。此外，由于能够穿过生物屏障，这里的HPP能够到达父药物可能无法进入或无法在目标区域产生足够浓度的区域，从而提供新的治疗方法。这里的HPP可以通过各种给药途径给予受试者。例如，由于其穿透生物屏障的能力，HPP可以在局部给药到疾病作用部位并以高浓度存在，从而避免系统性给药的需要。另一个例子是，这里的HPP可以被系统性地给药到生物体内，并以更快的速率进入循环系统。
• Borsche, Justus Liebigs Annalen der Chemie, 1908, vol. 359, p. 76
  作者：Borsche

  DOI：——

  日期：——
• Ullmann, Chemische Berichte, 1898, vol. 31, p. 1698
  作者：Ullmann

  DOI：——

  日期：——

表征谱图